Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$2.64
$0.06(2.40%)
At close: 4:00 PM EDT
$2.64
$0.06(2.40%)
Day’s Range― - ―
52-Week Range$1.70 - $14.86
Previous CloseN/A
Volume20.56K
Average Volume (3M)90.36K
Market Cap
$25.95M
Enterprise Value-$9.01M
Total Cash (Recent Filing)$26.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 16, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding9,979,298
10 Day Avg. Volume138,532
30 Day Avg. Volume90,365
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.13K
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$17.50Price Target Upside562.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure removes refinancing obligations and interest-rate exposure, preserving flexibility while ATOS funds clinical development. This is especially valuable for a clinical-stage biotechnology company because capital can be directed toward trials and regulatory work rather than debt servicing.
Clinical Pipeline ProgressProgress across breast-cancer and rare-disease programs broadens the potential value of (Z)-endoxifen and creates multiple clinical paths toward future catalysts. Completed enrollment and planned trials demonstrate continued development execution, although commercial success still depends on later clinical and regulatory outcomes.
Conditional Voucher-linked Shareholder AlignmentThe stapled CVR structure gives shareholders contractual participation in potential future voucher proceeds while preserving management discretion over development and capital allocation. Although payment is uncertain, the arrangement aligns investors with a possible long-term value event tied to the rare-disease pipeline.
Bears Say
No Commercial RevenueWithout approved commercial products, ATOS lacks a recurring revenue base to support research, development, and corporate expenses. Its financial outlook therefore depends on clinical progress, regulatory approvals, and future financing or partnership outcomes rather than established product demand or operating cash generation.
Worsening LossesLosses have widened materially over the reported periods, indicating that operating costs remain high relative to the company’s development-stage position and there is no demonstrated path to breakeven. Persistent losses can reduce financial resilience and increase reliance on external capital as programs advance.
Increasing Cash Burn And Funding PressureThe accelerating operating cash deficit shows that ATOS is not yet self-funding and requires substantial cash to sustain its pipeline. Continued burn raises the likelihood that additional capital may be needed, which can constrain development choices and create dilution risk for existing shareholders.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $1.70 and its highest was $14.86 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $25.95M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 22 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.075.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.86.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went down -2.479%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$17.50
▲(562.88% Upside)
Technical Analysis
Ownership Overview
2.17% Insiders
27.42% Mutual Funds
<0.01% Other Institutional Investors
66.52% Public Companies and
Individual Investors